Researchers at Weill Cornell Medicine identified a novel link between the IL-23 immune pathway and CTLA-4 in ILC3 cells, which plays a pivotal role in regulating inflammation and maintaining gut health, potentially impacting the treatment of inflammatory bowel diseases and cancer immunotherapy. Their findings could lead to more targeted therapies that balance immune response while preserving intestinal function in diseases like IBD and during cancer treatments. Credit: Ella Marushchenko and Kate Zvorykina (Ella Maru Studio) Weill Cornell scientists discovered a crucial link between two immune pathways involving IL-23 and CTLA-4, impacting the understanding and treatment of inflammatory bowel diseases and informing cancer immunotherapy strategies.
Scientists at Weill Cornell Medicine have uncovered a previously unknown connection between two key pathways that regulate the immune system in mammals. This discovery significantly enhances our understanding of chronic inflammatory bowel diseases (IBD), a group of disorders that severely affect the health and quality of life of over 2 million people in the United States. The immune system has many pathways to protect the body from infection, but sometimes an overactive immune response results in autoimmune diseases including IBD, psoriasis, rheumatoid arthritis, and multiple sclerosis.
Interleukin-23 (IL-23) is one such immune factor that fights infections but is also implicated in many of these inflammatory diseases. However, it wa.
